Technology ID
TAB-2373

Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors

E-Numbers
E-276-2011-0
Lead Inventor
Patnaik, Samarjit (National Human Genome Research Institute (NIH/NHGRI))
Applications
Therapeutics
Therapeutic Areas
Oncology
Development Status
  • Early-stage
  • In vitro data available
Lead IC
NCATS
Available for licensing are novel pyrrolopyrimidine compounds that disrupt the assembly of the perinucleolar compartment (PNC), a sub-nuclear structure highly prevalent in metastatic tumors. These notable compounds act without overt cytotoxicity.

The presence of the PNC positively correlates with metastatic capacity, making it a potential marker for cancer development and prognosis. These compounds could also serve as useful tools to elucidate the biology driving the formation and maintenance of the PNC, and unravel its association with metastasis.
Commercial Applications
  • Use in the therapeutic intervention of metastasis in cancer
  • Use as tools to elucidate the biology of the PNC
Competitive Advantages
  • No existing FDA-approved treatment for the clinical management of metastasis
  • Target is specific to metastatic tumors
  • Compounds are not toxic
  • Broadly acting across all metastatic cancers

Request More Info

Licensing Contact:
Vepa, Suryanarayana
sury.vepa@nih.gov

Patents

  • US
    Provisional (PRV) 61/576,780
    Filed on 2011-12-16
  • Patent Cooperation Treaty
    (PCT) PCT/US12/070155
    Filed on 2012-12-17
  • US Patent 9,663,521
    Filed on 2014-06-12
  • US Patent 10,301,314
    Filed on 2017-05-26

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact the NCATS Office of Strategic Alliances at NCATSPartnerships@mail.nih.gov.
Date Published